Mitotic vulnerability in triple-negative breast cancer associated with LIN9 is targetable with BET inhibitors

Triple-negative breast cancers (TNBC) are highly aggressive, lack FDA-approved targeted therapies, and frequently recur, making the discovery of novel therapeutic targets for this disease imperative. Our previous analysis of the molecular mechanisms of action of Bromodomain and extraterminal protein...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Res
Glavni autori: Sahni, Jennifer M., Gayle, Sylvia S., Webb, Bryan M., Weber-Bonk, Kristen L., Seachrist, Darcie D., Singh, Salendra, Sizemore, Steven T., Restrepo, Nicole A., Bebek, Gurkan, Scacheri, Peter C., Varadan, Vinay, Summers, Matthew K., Keri, Ruth A.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5626629/
https://ncbi.nlm.nih.gov/pubmed/28807940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-1571
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items